Insulet Corporation (PODD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$147.48-2.06%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Operating profit margin near 17.4% in 2025: TTM operating margin 16.9% vs 17.3% target.
Insulet grows revenue about 23% a year. Profit margin is near 17%. The company buys back shares to help shareholders. New product updates improve its insulin delivery system.
Product recalls and legal issues could hurt sales and reputation. Management changes add uncertainty. Guidance cuts show growth risks ahead.
The price is about 25% below our fair value near $215. Analysts expect 23% revenue growth. Our view aligns with this but sees risks from recent guidance cuts.
Breaks if: New major product recall or safety correction announced
Breaks if: Operating margin falls below 16% in FY25
Breaks if: YoY revenue growth falls below 22% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
PODD represents a durable compounder in the healthcare sector. The current thesis state is stable, supported by strong revenue growth and a favorable sector backdrop, although management execution has shown some volatility.
The market appears to have priced in a neutral valuation, with expectations slightly below peers. The company's execution quality is seen as weak, but this does not fully reflect the overall market sentiment.
Fundamentals are likely to continue showing strong revenue growth, with management focused on maintaining gross margins. However, there is an elevated risk due to potential guidance cuts and broader economic concerns.
The thesis hinges on management's ability to sustain revenue growth and margin targets, as well as the performance of key sector players. Economic indicators, such as job reports, could also impact sentiment and performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement. The advance in Omnipod 5 product innovation also boosts the outlook. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Repurchases drop below 1 million shares in next year
Insulet has expanded its share repurchase program to enhance shareholder value.
In the next 1 to 3 years, PODD's outlook will depend on management execution and sector dynamics. Not investment advice.